|
業務類別
|
Biotechnology |
|
業務概覽
|
Hemab Therapeutics Holdings Inc is a clinical-stage biotechnology company developing therapies for the treatment of blood coagulation disorders. It focuses on discovering, developing, and commercializing treatments for conditions such as Glanzmann thrombasthenia, Factor VII deficiency, and von Willebrand disease. Its flagship candidate, sutacimig (HMB-001), is a bispecific antibody currently in clinical trials for the prophylactic treatment of Glanzmann thrombasthenia and Factor VII deficiency. The company has one operating segment, engaged in the research and development of prophylactic therapeutics for bleeding disorders. |
| 公司地址
| 101 Main Street, Suite 1220, Cambridge, MA, USA, 02142 |
| 電話號碼
| +1 617 553-3952 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.hemab.com |
| 員工數量
| 72 |
| Dr. Benny Sorensen, M.D.,PhD |
Director, President and Chief Executive Officer |
-- |
10/04/2026 |
| Ms. Catherine Madigan, M.D. |
Chief Medical Officer |
-- |
10/04/2026 |
| Dr. Ananthram Sreenivasa Murthy, M.Sc. |
Chief Operating Officer |
-- |
10/04/2026 |
| Mr. Mads Behrndt-Eriksen, M. Sc. |
Chief Financial Officer, Chief Accounting Officer and General Manager |
-- |
10/04/2026 |
|
|
| Dr. John M. Maraganore,PhD |
Chairman of the Board |
10/04/2026 |
| Dr. Akshay K. Vaishnaw, M.D.,PhD |
Director |
10/04/2026 |
| Ms. Linda C. Bain |
Director |
10/04/2026 |
| Dr. Benny Sorensen, M.D.,PhD |
Director, President and Chief Executive Officer |
10/04/2026 |
|
|
|
|
